ASND earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E 26.95. Updated 2026-07-23.
Ascendis Pharma (ASND) Research Hub
Ascendis Pharma (ASND) trades on NASDAQ, DK in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 263.51 USD (+1.04%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 26.95, market cap 15.67B. This hub links to the full technical, earnings and options research available for ASND.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DK |
| Last close | 263.51 USD (+1.04%) |
| 52-week range | 218 USD – 282.15 USD |
| Trend regime | Range |
| 14-day RSI | 55.7 (Bullish) |
| Trailing P/E | 26.95 |
| Market cap | 15.67B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ASND
Covered Call on ASND: how it works, illustrative setup around the real 263.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ASND: how it works, illustrative setup around the real 263.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ASND: how it works, illustrative setup around the real 263.51 USD price, max profit/loss, breakeven and when to use it. Educational.
ASND technical analysis: range, last 263.51 USD, RSI 55.7, 52w range 218 USD–282.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ASND in?
Ascendis Pharma (ASND) is classified under Healthcare (Biotechnology), listed on NASDAQ, DK.
Is ASND in an uptrend or downtrend?
As of 2026-09-11, ASND is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ASND's trailing P/E ratio?
ASND's trailing P/E is 26.95, with a market cap of 15.67B. See the earnings research page for full valuation detail.
When does ASND next report earnings?
ASND is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 1.29 USD.